Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2019-06-19 Director's Dealing
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-19 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 15, 2019, by Sutro Biopharma, Inc. It specifically mentions Item 7.01 Regulation FD Disclosure and states that a presentation (Exhibit 99.1) was furnished at the 2019 European Hematology Association Congress. The text clarifies that the information is furnished and not filed, and it includes a presentation attachment. The document is short (3307 characters) and primarily serves to disclose the presentation event rather than containing detailed financial data or a full report. This matches the characteristics of an Investor Presentation (IP) filing type, as it focuses on a presentation for investors or the public about company information at a conference. It is not an Annual Report, Earnings Release, or other financial report, nor is it a regulatory filing or announcement of a report publication. Therefore, the best classification is Investor Presentation (IP).
2019-06-17 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 7, 2019, by Sutro Biopharma, Inc. It reports the resignation of a board member and the appointment of a new audit committee member, which is a change in the company's board or senior management. Additionally, it includes the results of the 2019 Annual Meeting of Stockholders, detailing votes on director elections and auditor ratification. The presence of Item 5.02 (Departure of Directors or Principal Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders) indicates this is primarily a management and voting results announcement. Since it includes both management changes and voting results, the more specific classification is Declaration of Voting Results & Voting Rights Announcements (DVA), as the voting results are explicitly detailed and this is a common use of Form 8-K. The document length is under 5,000 characters and is a current report, not a full annual or quarterly report. Therefore, the best fit is DVA with high confidence.
2019-06-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2019, by Sutro Biopharma, Inc. It announces the issuance of a press release regarding financial results for the period ended March 31, 2019. The document itself is a current report that includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis. The text explicitly states that the information is being furnished and is not "filed" for purposes of Section 18, indicating it is an announcement rather than a full report. The document length is 3590 characters, which is relatively short and consistent with an announcement rather than a full earnings release or interim report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or press releases without full financial data.
2019-05-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.